Mostrando 2 resultados de: 2
Filtros aplicados
Subtipo de publicación
Article(2)
Lowering cholesterol, blood pressure, or both to prevent cardiovascular events: Results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants
ArticleAbstract: Aims: Rosuvastatin (10 mg per day) compared with placebo reduced major adverse cardiovascular (CV) ePalabras claves:Cardiovascular disease, Primary Prevention, statinsAutores:Avezum A.J., Bosch J.J., Dagenais G.R., Dans A.M., DIaz R., Held C., Jansky P., Joseph P.G., Jung H., Keltai K., Keltai M., Khunti K., Leiter L.A., Lewis B.S., Liu L., Lonn E.M., Pais P., Parkhomenko A.N., PATRICIO LOPEZ -JARAMILLO, Peters R.J.G., Piegas L.S., Reid C.M., Sliwa K., Toff W.D., Varigos J.D., Xavier D., Yusoff K., Yusuf S., Zhu J.Fuentes:googlescopusThe cost implications of a polypill for primary prevention in the TIPS-3 trial
ArticleAbstract: Aims The International Polycap Study 3 (TIPS-3) trial demonstrated that a polypill containing cholesPalabras claves:Cardiovascular disease, cost analysis, Polypill, Primary PreventionAutores:Dans A.L., Gamra H., Gao P., Joseph P.G., Lamy A., Pais P., PATRICIO LOPEZ -JARAMILLO, Santoso A., Talukder S.H., Tong W., Walli-Attaei M., Xavier D., Yusuf S.Fuentes:googlescopus